Company / R&D per Share
MANNKIND CORP R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.22
FY2025
5-year range
$0.05 / $0.22
FY2021-FY2025
Trend
+28.9%
vs FY2024
Sector context
#190 of 207
Health Care
What the data says
Among 207 Health Care companies, MANNKIND CORP is in the bottom 8% for r&d per share. R&D per Share has increased for 5 consecutive years, from $0.03 in FY2020 to $0.22 in FY2025.
Based on SEC 10-K filings.
0.22 in FY2025 with a 5-year CAGR of +49.3%.
Improved from $0.12 to $0.22 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +40.8%
- 5-Year CAGR
- +49.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 207This company $0.22 Sector average $12.26
▼
-98.2% below sector average
Key checks
Key Insights
- MANNKIND CORP's r&d per share has grown for 5 consecutive years.
- In FY2025, r&d per share increased 28.9% year-over-year.
- Ranks #190 out of 207 companies in the Health Care sector.
- Lowest r&d per share in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -2.74 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.22 | +28.9% |
| FY2024 | $0.17 | +43.3% |
| FY2023 | $0.12 | +51.2% |
| FY2022 | $0.08 | +54.2% |
| FY2021 | $0.05 | +72.4% |
| FY2020 | $0.03 | -20.0% |
| FY2019 | $0.04 | -49.7% |
| FY2018 | $0.07 | -50.3% |
| FY2017 | $0.15 | -15.2% |
| FY2016 | $0.17 | +138.1% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026